People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder, ...

Johnson & Johnson’s Spravato nasal spray has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe ...

Johnson & Johnson’s Spravato nasal spray has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced ...